ESMO 2024 – Torl challenges BioNTech in Claudin6
Efficacy with Torl’s ADC looks in line, while toxicity with BNT211 still looms large.
Efficacy with Torl’s ADC looks in line, while toxicity with BNT211 still looms large.
If the therapeutic window remains open, OncoC4/BioNTech’s gotistobart could hold promise.
Incyte’s first substantial data with INCB123667 are eclipsed by Pfizer’s PF-07104091/atirmociclib combo.
An initial winner of the ASCO abstract reveal, Verastem drops a bombshell.
The group reckons big pharma is eyeing KIF18A inhibition, but for now there are just a handful of players.
Genmab’s remarkably bold acquisition raises more questions about Sutro, a key FRα rival of ProfoundBio.